MediPharm Labs Corp.
MEDIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $42 | $33 | $22 | $22 |
| % Growth | 26.9% | 49.5% | 1.9% | – |
| Cost of Goods Sold | $29 | $27 | $24 | $37 |
| Gross Profit | $13 | $6 | -$2 | -$15 |
| % Margin | 30.5% | 17.7% | -8.7% | -70.2% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $20 | $22 | $18 | $18 |
| SG&A Expenses | $23 | $25 | $25 | $23 |
| Sales & Mktg Exp. | $3 | $3 | $6 | $5 |
| Other Operating Expenses | $1 | -$1 | $1 | $3 |
| Operating Expenses | $24 | $24 | $27 | $28 |
| Operating Income | -$11 | -$18 | -$30 | -$49 |
| % Margin | -25.8% | -55.2% | -133.5% | -225.3% |
| Other Income/Exp. Net | $0 | $5 | -$0 | -$6 |
| Pre-Tax Income | -$11 | -$13 | -$30 | -$55 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$11 | -$13 | -$30 | -$55 |
| % Margin | -25.5% | -39.6% | -135.6% | -252.4% |
| EPS | -0.026 | -0.036 | -0.11 | -0.22 |
| % Growth | 27.2% | 67.3% | 50% | – |
| EPS Diluted | -0.026 | -0.036 | -0.11 | -0.22 |
| Weighted Avg Shares Out | 408 | 363 | 277 | 250 |
| Weighted Avg Shares Out Dil | 408 | 363 | 277 | 250 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $11 |
| Depreciation & Amortization | $3 | $3 | $4 | $12 |
| EBITDA | -$8 | -$10 | -$25 | -$39 |
| % Margin | -17.9% | -31.7% | -115% | -177.6% |